

Instructions for Authors 2019

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis. The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to peer-review, when appropriate, by two members of the Editorial Board. All manuscripts submitted to IN VIVO are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

Open Access Policy. IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 575.00 for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 58.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume and issue numbers, as well as page numbering.

Copyright. Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of IN VIVO articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in IN VIVO are the property of the publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors' contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear **at the end** of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are not subject to color charges.

Tables. All tables should appear **at the end** of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of “Index Medicus” and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O’Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. References should include PMID and DOI (if applicable).

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “NCT”). Please note that there is no space between the prefix “NCT” and the number. Example: NCT00001789.

Ethical Policies and Standards. IN VIVO agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. In Vivo (IV) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.
3. Each manuscript submitted to IV is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to IV, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

4. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
5. Authors should pay attention to the following points when writing an article for IN VIVO:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
8. Articles submitted to IN VIVO may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to IV.
 - plagiarism is detected by plagiarism screening services.(Rejection rate (2016): 59%).
9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org.
11. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of IV).

Serum Lactate Dehydrogenase Contributes to Prognostic Assessment in Patients With Oligometastatic Cancer and Brain Involvement. C. NIEDER, A. DALHAUG, A. PAWINSKI (<i>Bodø; Tromsø, Norway</i>)	229
A Qualitative Analysis of the Impact of Carboplatin AUC 10 on Physical, Work Functioning and Bone Marrow Toxicity Among Seminoma Patients – A Single-centre Experience. M. MILIC, M. HALL, A. HAWKINS, A. GOGBASHIAN, G. RUSTIN, A. SHARMA (<i>Northwood, UK</i>).....	233
Anthropometric Assessment After Proctocolectomy Due to Ulcerative Colitis. H. KAWAHARA, Y. HIRAMOTO, M. TAKEDA, N. MATSUMOTO, T. MISAWA, K. YANAGA (<i>Chiba; Tokyo, Japan</i>).....	239
Clinical Influence of Ploidy and Cancer Stem Cells and Other Parameters in Stage IV Colorectal Cancer. K.A. POLYZOS, M.L. KARADIMA, A.C. KOSMA, A. LAZARIS, N. KAVANTZAS, N. TSAVARIS (<i>Athens; Piraeus, Greece</i>)	245
Small Bowel Pyogenic Granuloma With Cytomegalovirus Infection in a Patient With Crohn’s Disease (Report of a Case and Review of the Literature). D. ZHANG, S.C. GLOVER, W. LIU, X. LIU, J. LAI (<i>Gainesville, FL; Rochester, NY, USA; Changsha, PR China</i>).....	251
Mid- to Long-term Outcomes After Weber B-type Ankle Fractures With and Without Syndesmotic Rupture. M.B.J. KOHAKE, U. WIEBKING, P.F. O’LOUGHLIN, C. KRETTEK, R. GAULKE (<i>Hanover, Germany; Cork, Ireland</i>)	255
Risk Factors for Recurrence of Malignant Phyllodes Tumors of the Breast. H.J. PARK, H.S. RYU, K. KIM, K.H. SHIN, W. HAN, D.-Y. NOH (<i>Seoul, Republic of Korea</i>)	263
Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis. T. SASAKI, R. KANATA, I. YAMADA, M. MATSUYAMA, M. OZAKA, N. SASAHIRA (<i>Tokyo, Japan</i>)	271
Presence of CD34 ⁺ in Megakaryocytes in Association With p53 Expression Predicts Unfavorable Prognosis in Low-risk Myelodysplastic Syndrome Patients. F.B. DUARTE, T.E.D.J. DOS SANTOS, M.C. BARBOSA, A.T.G. MOURA, J.P.L. DE VASCONCELOS, F.D. ROCHA-FILHO, D.F. COUTINHO, I. ZALCBERG, P.R.L. VASCONCELOS, Y.D.O. GARCIA, R.P.G. LEMES (<i>Fortaleza; Rio de Janeiro, Brazil</i>).....	277
Response to First-line Recurrence Treatment Influences Survival in Hormone Receptor-positive, HER2-negative Breast Cancer: A Multicenter Study. J. YAMAMURA, S. KAMIGAKI, M. TSUJIE, J. FUJITA, H. OSATO, C. HIGASHI, H. KANAIZUMI, Y. TANAKA, M. HAMADA, W. SHINZAKI, Y. HASHIMOTO, Y. KOMOIKE (<i>Osaka, Japan</i>)	281

Characteristics and Outcomes of Extreme Elderly Patients With Hepatocellular Carcinoma in South Korea. J.H. SEO, D.H. KIM, E. CHO, C.H. JUN, S.Y. PARK, S.B. CHO, C.H. PARK, H.S. KIM, S.K. CHOI, J.S. REW (<i>Gwangju, Republic of Korea</i>)	145
β -Hydroxy- β -methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma. A. NAGANUMA, T. HOSHINO, N. OHNO, Y. OGAWA, T. MURAKAMI, S. HORIGUCHI, D. UEHARA, Y. SUZUKI, T. HATANAKA, T. KUDO, H. ISHIHARA, K. SATO, S. KAKIZAKI, H. TAKAGI (<i>Takasaki; Maebashi; Fujioka, Japan</i>)	155
Phase II Study of Weekly Amrubicin for Refractory or Relapsed Non-small Cell Lung Cancer. C. KITAGAWA, M. IWASAKU, Y. KOGURE, M. ANDO, H. YOSHIOKA, A. NISHIYAMA, N. WATANABE, K. KUNIMASA, K. TSUBOUCHI, S. OKA, H. SAKA (<i>Nagoya; Kurashiki; Osaka, Japan</i>)	163
Gemcitabine Plus Cisplatin Split Versus Gemcitabine Plus Carboplatin for Advanced Urothelial Cancer With Cisplatin-unfit Renal Function. K. IZUMI, H. IWAMOTO, H. YAEGASHI, K. SHIGEHARA, T. NOHARA, Y. KADONO, A. MIZOKAMI (<i>Kanazawa, Japan</i>)	167
Patterns of Treatment and Outcome in Patients With 20 or More Brain Metastases. C. NIEDER, R. YOBUTA, B. MANNSÅKER (<i>Bodø; Tromsø, Norway</i>)	173
Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC. A.R. BUONOMO, R. SCOTTO, E. ZAPPULO, M. NERILLI, B. PINCHERA, G. PERRUOLO, P. FORMISANO, S. NAPPA, I. GENTILE (<i>Naples, Italy</i>)	177
Relationship Between Renal Dysfunction and Oral Mucositis in Patients Undergoing Concurrent Chemoradiotherapy for Pharyngeal Cancer: A Retrospective Cohort Study. H. MIZUNO, H. MIYAI, A. YOKOI, T. KOBAYASHI, C. INABU, T. MARUYAMA, D. EKUNI, N. MIZUKAWA, S. KARIYA, K. NISHIZAKI, Y. KIMATA, M. MORITA (<i>Komaki; Okayama, Japan</i>)	183
Clinical Study of Reconstruction Plates Used in the Surgery for Mandibular Discontinuity Defect. G. KAWASAKI, N. IMAYAMA, I. YOSHITOMI, K. FURUKAWA, M. UMEDA (<i>Nagasaki; Isahaya, Japan</i>)	191
Neutrophil-to-Lymphocyte Ratio Predicts Survival After Whole-brain Radiotherapy in Non-small Cell Lung Cancer. H. DOI, K. NAKAMATSU, S. ANAMI, K. FUKUDA, M. INADA, H. TATEBE, K. ISHIKAWA, S. KANAMORI, H. MONZEN, Y. NISHIMURA (<i>Osaka-Sayama, Japan</i>)	195
Fusion Imaging of Contrast-enhanced Ultrasound With CT or MRI for Kidney Lesions. T. AUER, I. HEIDEGGER, T. DE ZORDO, D. JUNKER, W. JASCHKE, F. STEINKOHL, F. AIGNER (<i>Hall in Tirol; Innsbruck, Austria; Brixen, Italy</i>)	203
Ultrasonography-guided Suction Thrombectomy for an Isolated Portal Vein Thrombus in Liver Surgery. Y.-I. YAMASHITA, K. IMAI, S. NAKAGAWA, Y. NAKAO, T. YUSA, R. ITOYAMA, H. OKABE, H. HAYASHI, A. CHIKAMOTO, H. BABA (<i>Kumamoto, Japan</i>)	209
Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody. T. KIRIU, M. YAMAMOTO, T. NAGANO, K. KOYAMA, M. KATSURADA, D. TAMURA, K. NAKATA, M. TACHIHARA, K. KOBAYASHI, Y. NISHIMURA (<i>Kobe, Japan</i>)	213
Comparison of Weight and Body Composition After Gastrectomy Between Elderly and Non-elderly Patients With Gastric Cancer. T. AOYAMA, Y. MAEZAWA, T. YOSHIKAWA, K. SEGAMI, K. KANO, T. HAYASHI, T. YAMADA, M. NUMATA, M. GODA, H. TAMAGAWA, T. SATO, N. YUKAWA, Y. RINO, M. MASUDA, T. OGATA, H. CHO, T. OSHIMA (<i>Yokohama, Japan</i>)	221

Effects of Medium Molecular Weight Heparinyl Phenylalanine on Type I Hypersensitivity. S. TAKEDA, T. TODA, K. NAKAMURA (<i>Osaka; Nishinomiya, Japan</i>)	53
Heteroplasmic Mutations and Polymorphisms in the <i>Cyb</i> Gene of Mitochondrial DNA in Canine Mast Cell Tumours. A. ŚMIECH, B. ŚLASKA, A. BOWNIK, L. GRZYBOWSKA-SZATKOWSKA, J. DUDKA, W. ŁOPUSZYŃSKI (<i>Lublin, Poland</i>).....	57
Maslinic Acid Enhances Immune Responses in Leukemic Mice Through Macrophage Phagocytosis and Natural Killer Cell Activities <i>In Vivo</i> . K.-C. LAI, S.-F. PENG, C.-C. LIU, J.-Y. HUANG, J.-Y. KUO, Z.-Y. CHENG, R.S.-C. WU, C.-C. LIN, JR-K. CHEN, J.-G. CHUNG (<i>Tainan; Beigang; Taichung; Hsinchu; Changhua, Taiwan, ROC</i>).....	65
The Healing Effect of Platelet-rich Plasma (PRP) Jelly in Rabbits Undergoing Tracheal Resection and Anastomosis. J.Y. LEE, S.J. SON, S.H. CHOI, D.-W. CHO (<i>Pohang; Seoul; Cheongju, Republic of Korea</i>)	75
SOX 2 Expression in Human Pituitary Adenomas–Correlations With Pituitary Function. C. CAPATINA, A.M. CIMPEAN, M. RAICA, M. COCULESCU, C. POIANA (<i>Bucharest; Timisoara, Romania</i>)	79
Retinoic Receptor Signaling Regulates Hypertrophic Chondrocyte-specific Gene Expression. T. SHIMO, E. KOYAMA, T. OKUI, M. MASUI, Y. KUNISADA, S. IBARAGI, N. YOSHIOKA, N. KURIO, S. YOSHIDA, A. SASAKI, M. IWAMOTO (<i>Ishikari-Tobetsu; Okayama; Tokushima, Japan; Philadelphia, PA; Baltimore, MD, USA</i>).....	85
Suppressive Activity of Adiponectin on the Development of Allergic Rhinitis in Mice. S. FURUKAWA, K. ASANO, H. KOBAYASHI (<i>Tokyo; Yokohama, Japan</i>)	93
The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth <i>In Vivo</i> than Either Drug Alone. L.N.K. TRAN, G. KICHENADASSE, K.L. MOREL, T.C. LAVRANOS, S. KLEBE, K.M. LOWER, R.J. ORMSBY, D.J. ELLIOT, P.J. SYKES (<i>Adelaide; Thebarton, South Australia; Ho Chi Minh, Vietnam</i>).....	99
<i>Clinical Studies</i>	
The Effect of Lipopolysaccharide-containing Moisturizing Cream on Skin Care in Patients With Mild Atopic Dermatitis. K. NAKAI, Y. KUBOTA, G.-I. SOMA, C. KOHCHI (<i>Kita-gun; Takamatsu, Japan</i>).....	109
Comparative Assessment of CPET Versus Typical Work-related Activities in Women With and Without Mild COPD. J. SCHNEIDER, I.L. GIESSER, S. LAUX, U. BRÁCKNER, S. SCHNEIDER-LAUTEREN (<i>Giessen, Germany</i>).....	115
A Study of the Relation Between Mastectomy Specimen Weight and Volume With Implant Size in Oncoplastic Reconstruction. U. WAZIR, H. EL HAGE CHEHADE, C. CHOY, A. KASEM, K. MOKBEL (<i>London, UK</i>).....	125
Limited Influence of Flail Chest in Patients With Blunt Thoracic Trauma – A Matched-pair Analysis. P. GETZ, P. MOMMSEN, J.-D. CLAUSEN, M. WINKELMANN (<i>Hannover, Germany</i>).....	133
Chitinase-3-like Protein 1 (YKL-40) Is Expressed in Lesional Skin in Hidradenitis Suppurativa. J. SALOMON, A. PIOTROWSKA, Ł. MATUSIAK, P. DZIĘGIEL, J.C. SZEPIETOWSKI (<i>Wrocław, Poland</i>)	141